BPC-157 dosing has never been set for humans. The schedules you see online come mostly from rat studies, and the human data covers 30 people. Here is what research used, and why a provider at telos rx sets any dose.
Written by the telos rx Editorial Team. Last reviewed: 17 November 2026.
How we built this guide
- What we compared: the dosing patterns described in published BPC-157 research, in animals and in people.
- How: we read recent systematic and narrative reviews indexed on PubMed and noted the study type, route, frequency and length of each pattern.
- Who: the telos rx Editorial Team.
- Date checked: 17 November 2026.
- What this is not: a dosing guide. No pattern below is a schedule to follow.
Search for BPC-157 dosing and you will find charts, calculators and confident protocols. They look precise. The evidence underneath them is thin, and most of it comes from rodents.
This guide walks through the dosing schedules that research actually used. Each one is labelled as animal or human evidence. You will also see why none of them works as a plan for a real person.
The short answer on BPC-157 dosing
There is no validated human dose of BPC-157. No large, controlled human trial has tested it for any use. Regulators have not reviewed a dose, because the compound has never completed the trials needed for FDA approval.
What exists is a long list of animal experiments and three tiny human studies. Researchers chose doses to answer lab questions. They were not trying to find a safe, effective regimen for people.
- Animal evidence: large in volume, varied in design, mostly from a small number of research groups.
- Human evidence: three small studies with 30 people in total, all rated poor quality.
- Bottom line: any dose for you is set by a prescribing provider, not by a chart.
Why BPC-157 dosing is so hard to pin down
Dosing a medicine usually rests on years of trials. Researchers test a range of doses in people. They measure blood levels, benefits and side effects, then pick a dose that balances them.
BPC-157 skipped all of that. Its research history is mostly injury models in rats and mice. Those studies used doses scaled to tiny body weights, given by routes rarely used in people.
Turning an animal dose into a human dose is not simple arithmetic. Body size, metabolism and absorption all differ. A 2025 systematic review in HSS Journal noted that preclinical work suggests BPC-157 has a half-life of under 30 minutes in animal models. Nobody has mapped how it behaves in people over weeks.
That is why we describe the schedules below as research history. They tell you what scientists tried. They do not tell you what is safe or useful for you.
6 BPC-157 dosing patterns found in research
Here are the main schedule patterns that appear in published BPC-157 studies. We list them in order of how often they appear, from most to least common.
1. Once-daily injections in animal injury models
Evidence type: animal. This is the most common pattern by far. A 2025 narrative review of BPC-157 for musculoskeletal healing found that most animal studies gave it once daily.
Regimens ranged from a single dose to daily dosing for 7, 14, 28 or up to 90 days. The length depended on the injury model and what researchers wanted to measure. Doses were scaled to the weight of a rat or mouse.
What it can and cannot tell you: it shows how labs designed their experiments. It cannot show that daily dosing helps people, or that it is safe for people over weeks.
2. BPC-157 in drinking water
Evidence type: animal. Some rodent studies added BPC-157 to the animals' drinking water. This was a convenient way to give an oral form over many days.
The exact amount each animal drank was hard to control. That makes these studies a weak guide to oral dosing in people. Human oral absorption of BPC-157 has not been properly studied.
What it can and cannot tell you: it explains why oral BPC-157 is discussed at all. It does not show that a capsule or liquid works the same way in a human gut.
3. Local and topical application
Evidence type: animal. Other animal studies applied BPC-157 directly at or near the injury site. Some used creams or local injections in wound and tendon models.
These designs answered questions about local tissue effects in rodents. They varied widely in amount and method, so the results are hard to compare.
What it can and cannot tell you: it shows researchers were curious about local effects. It does not establish any topical regimen for people.
4. Single doses and very short courses
Evidence type: animal. Some experiments gave just one dose, or a few doses over a few days. These studies often looked at early changes in tissue or blood flow.
Short designs are useful in the lab. They say little about what happens with longer use, which is how most people online describe taking it.
What it can and cannot tell you: short courses in animals do not tell you about long-term safety in people.
5. Injection into the knee in a small human study
Evidence type: human, very limited. One retrospective study looked back at 16 people who received BPC-157 injected into the knee for knee pain. Some also received a second peptide, thymosin beta-4, in the same injection.
The study had no control group. People were contacted months later to report their pain. That design is open to recall bias and placebo effects.
What it can and cannot tell you: it shows that clinicians have tried this route. It cannot show that the dose used was right, or that BPC-157 caused any change.
6. Bladder instillation and an intravenous safety test
Evidence type: human, very limited. A pilot study placed BPC-157 directly into the bladder in 12 people with interstitial cystitis. A separate pilot gave intravenous BPC-157 to 2 healthy adults to look at safety.
Neither study had a control group. Neither was designed to find the right dose for general use. The intravenous study involved only two people, which cannot detect uncommon side effects.
What it can and cannot tell you: these are early safety and feasibility signals. They are not a dosing schedule for anyone.
What the human evidence adds up to
A 2026 systematic review of human BPC-157 studies searched the medical literature up to June 2026. It found only the three human studies above, with 30 people in total.
The studies reported symptom changes and no adverse events linked to BPC-157. But the review judged all three to be of poor methodological quality. It rated the overall certainty of evidence as very low.
The authors concluded that BPC-157 should not be used clinically outside ethically reviewed, regulated, high-quality clinical trials. That is the most important context for any dosing question.
The earlier 2025 systematic review in HSS Journal reached a similar point. It included 36 studies, and 35 of them were preclinical. It found no clinical safety data.
Animal vs human evidence at a glance
| Pattern | Evidence type | Size of evidence | Useful as a human schedule? |
|---|---|---|---|
| Once-daily injections | Animal | Many rodent studies | No |
| Drinking water | Animal | Some rodent studies | No |
| Local or topical | Animal | Some rodent studies | No |
| Single or short course | Animal | Some rodent studies | No |
| Knee injection | Human | 16 people, no control group | No |
| Bladder and intravenous pilots | Human | 14 people, no control group | No |
Considering BPC-157 through a licensed provider?
telos rx offers compounded BPC-157 as a single-ingredient product after an online clinical review. It is not FDA-approved, and any prescription is subject to medical approval by a licensed provider.
Learn about BPC-157Why online BPC-157 dosing charts are a problem
Many websites show a BPC-157 dosing chart with neat numbers. Some offer calculators. These tools look scientific, but they rest on guesswork.
- They scale up rat doses. Converting a rodent dose to a human dose involves assumptions that have never been tested for BPC-157.
- They ignore the product. Online products sold for research use only may not contain what the label says.
- They skip the person. A chart cannot account for your health history, medicines or reasons for asking.
- They imply certainty. A tidy table suggests the dose has been tested. It has not.
That is why this guide has no dosing table. At telos rx, medication ships ready to use. You never need to mix, measure from a powder or work out a dose yourself.
Cycle length and timing: what research says
Online protocols often talk about cycles, such as a few weeks on and some weeks off. They also debate morning versus evening use, or taking it with or without food.
Animal evidence: study lengths ranged from a single dose to 90 days. Those lengths reflected each experiment's design. They were not tests of on and off cycles.
Human evidence: no study has compared cycle lengths, rest periods or time of day in people. Any claim about the best cycle is opinion, not data.
If you are prescribed BPC-157, your provider decides how long you use it and when to stop. They can also review how you are doing along the way.
Routes of use and the HHS policy
Research has used several routes, as the list above shows. In the US, the route also matters for regulation.
On 30 October 2026, HHS published an interim enforcement discretion policy in the Federal Register, document 2026-22192. For BPC-157, it covers subcutaneous, intramuscular, oral and topical use. It requires a single active ingredient, a valid patient-specific prescription and FDA-registered ingredient suppliers.
This policy is not FDA approval. It is not a final listing, and HHS can revise it. Our full explainer on the HHS peptide policy covers every condition. This summary reflects the policy as checked on 17 November 2026.
Safety questions dosing cannot answer
Even a carefully chosen dose cannot fill the gaps in BPC-157 safety data. Here is what remains unknown in people.
- Long-term effects: no human study has followed people for months or years.
- Blood vessel growth: animal studies suggest BPC-157 affects new blood vessel formation. Researchers have asked whether that matters for people with cancer or a history of cancer. There is no human data.
- Pregnancy and breastfeeding: no human safety data.
- Interactions: not studied in people. Tell your provider about every medicine and supplement you take.
- Quality: unregulated products may be contaminated or mislabelled.
Our guide to what BPC-157 is covers these unknowns in more depth. You can also read which labs providers sometimes check in our peptide therapy blood work guide.
Seek urgent care for signs of a serious allergic reaction, such as swelling of the face or throat, or trouble breathing. Contact your clinician about any new or worrying symptom, such as injection-site redness that spreads, fever or unusual pain.
Who should be especially cautious
Some people have even less information to go on. Talk this through carefully with a clinician if any of these apply.
- People with active cancer or a past history of cancer.
- People who are pregnant, trying to conceive or breastfeeding.
- People under 18.
- People with serious heart, kidney or liver conditions.
- People taking several prescription medicines.
- Athletes in tested sport, since BPC-157 is prohibited under category S0 of the WADA Prohibited List.
A licensed provider may decide BPC-157 is not right for you. That is a normal, responsible outcome of a clinical review.
BPC-157 and standard care
People often look up BPC-157 dosing because of an injury, joint pain or gut symptoms. For those problems, standard care has far more evidence behind it.
That includes a medical evaluation, imaging when needed, physical therapy, graded exercise, sleep and good nutrition. BPC-157 is not a substitute for any of these. Some causes of pain need specific care that a peptide cannot replace.
Our review of recovery peptide research compares the evidence across several peptides and standard approaches.
Questions to ask a provider about BPC-157 dosing
- What evidence supports using BPC-157 for my situation?
- How will you choose the dose, route and length of use?
- What side effects should I watch for, and when should I contact you?
- How will we decide whether to continue or stop?
- Which state-licensed pharmacy prepares the product?
- Is it a single-ingredient product with a clear label?
- What will it cost, given how thin the evidence is?
Our guide to peptide therapy cost explains what you may pay and why prices vary.
How telos rx approaches BPC-157 dosing
telos rx is an online-first, asynchronous telehealth service. You complete a private intake online, on your schedule. A licensed provider reviews it, and you message your care team with questions.
If prescribed, compounded BPC-157 is prepared by a state-licensed pharmacy as a single-ingredient product. Your provider determines the dose and form. Medication ships ready to use, so there is nothing to mix or calculate.
The telos rx BPC-157 page lists it as low as $116 per month, as of 17 November 2026. Every prescription is subject to medical approval by a licensed provider, and approval is not guaranteed.
If you are curious about BPC-157 alongside TB-500, telos rx offers them only as two separate single-ingredient vials, never one blend. See the BPC-157 and TB-500 page for details.
The bottom line on BPC-157 dosing
BPC-157 dosing schedules in research were built for rodents and lab questions. The human evidence is three small studies with 30 people, rated very low certainty.
That means no chart can tell you the right dose. A licensed provider can weigh the thin evidence, your health history and the unknowns, then decide whether BPC-157 fits at all.
Change log: published 17 November 2026.
Start a private peptide evaluation
Answer health questions online, on your schedule. A licensed provider reviews them, and any prescription is subject to medical approval by a licensed provider.
Check my eligibilityFrequently Asked Questions
Is there a validated BPC-157 dose for humans?
No. There is no validated human dose for BPC-157. Almost all dosing information comes from rat and mouse studies, and the few human reports were small and uncontrolled. For a real person, the prescribing provider sets any dose, route and schedule after a clinical review. A research paper or website cannot.
Where do the BPC-157 dosing schedules online come from?
Most come from animal studies, scaled up to human body weight by sellers or forum users. That scaling is guesswork. Animal studies were designed to answer lab questions, not to find a safe human regimen. Read any online schedule as research history or marketing, never as instructions to follow.
How often was BPC-157 given in animal studies?
A 2025 narrative review found that most musculoskeletal animal studies gave BPC-157 once daily. Regimens ranged from a single dose to daily dosing for 7, 14, 28 or up to 90 days, depending on the injury model. These were lab protocols in rodents and do not tell you what is right for a person.
What doses were used in human BPC-157 studies?
Only three small human studies exist, with 30 people in total. They used injection into the knee, instillation into the bladder and an intravenous safety test. A 2026 systematic review rated all three as poor quality with very low certainty. None of them set a dose for general use.
Does telos rx publish a BPC-157 dosing schedule?
No. telos rx does not publish a dosing schedule for BPC-157. If a licensed provider prescribes it after an online review, the provider determines the dose and form. Medication ships ready to use, and you can message your care team with questions. Every prescription is subject to medical approval by a licensed provider.
Does compounded BPC-157 have FDA approval?
No. Compounded BPC-157 is not FDA-approved. HHS published an interim enforcement discretion policy on 30 October 2026 that covers compounding BPC-157 under strict conditions. That policy is not approval, is not a final rule and can be revised. Check the latest version before relying on it.
telos rx is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.
Ready to see if it fits? Start your private evaluation with telos rx.